Biora Therapeutics Shares Presentation of Patient Data Establishing Correlation Between Drug Levels in Colon and Patient Outcomes in Ulcerative Colitis

Oral Presentation Delivered at DDW 2022 Informs Clinical Study Design for Biora’s Targeted Therapeutics Platform

SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared a presentation delivered during Digestive Disease Week® (DDW), May 21-24, 2022 in San Diego. DDW is the world’s premier meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

Key opinion leader Dr. Séverine Vermiere gave a presentation titled “Tofacitinib tissue exposure correlates with endoscopic outcome,” which Dr. Vermiere co-authored with lead author Dr. Bram Verstockt and others. In the presentation, Dr. Vermiere presented patient data confirming a significant relationship between drug levels in tissue and endoscopic improvement in patients with moderate to severe ulcerative colitis (UC) who were treated with tofacitinib.

“This study supports the hypothesis that a tissue concentration of tofacitinib at or exceeding IC90 is directly correlated to significant improvement in patient outcomes,” Adi Mohanty, Chief Executive Officer of Biora Therapeutics.

“Our targeted delivery platform is uniquely positioned to be able to safely deliver the desired amount of drug to the diseased tissue in UC. Our phase 1 clinical study planned to begin later this year, along with the various safety data, will provide us with valuable information on concentrations of tofacitinib in tissue as well as the level of systemic exposure,” continued Mr. Mohanty. “We recently also shared data about the potential importance of combination therapy for the UC patient community. Reducing systemic uptake with PGN-600 could enable combination therapy to target multiple inflammatory pathways. We believe our approach could allow for multiple ways to improve therapeutic outcomes for the large number of UC patients who are still significantly lacking in options.”

Séverine Vermeire, MD, Ph.D., is Head of the Department of Chronic Diseases & Metabolism (CHROMETA) at KU Leuven. Since 2003, Dr. Vermeire has been a staff member at the Gastroenterology Department of the University Hospitals Leuven and was appointed Full Professor of Medicine at the KU Leuven. Dr. Vermeire obtained her MD degree and then her PhD at the KU Leuven. She further trained at the Universidad Nacional de Asuncion, Paraguay, at the Wellcome Trust Centre for Human Genetics, University of Oxford, UK, and at the Montreal General Hospital (McGill University) in Canada. She is actively involved as principal investigator in randomized clinical trials with new therapeutic compounds and has been lead investigator on several of these programs. Dr. Vermeire’s scientific work resulted in more than 500 peer-reviewed articles and focuses on the role of the microbiome and genetic susceptibility in IBD and on identifying predictive signatures of treatment response.

Bram Verstockt, MD, Ph.D., is a consulting gastroenterologist (IBD team) in the Gastroenterology Department of the University Hospitals Leuven at KU Leuven. His translational research is focused primarily on the development of predictive and prognostic markers for a more personalized medicine in IBD, as well as on further unraveling IBD disease heterogeneity. He co-founded the international COLLIBRI proteomics consortium in IBD. He is a member of the editorial board of the Journal of Crohn’s and Colitis, and reviewer for many gastroenterology journals and conferences. Dr. Verstockt has received several awards including the Prijs Prof. Dr. Jan De Grootte in 2013 and the Horlait-Dapsens Prize in 2020.

Presentation slides can be viewed by visiting bioratherapeutics.com/publications, and a video of Dr. Vermiere’s presentation will be posted on the DDW conference website in mid June.

About Biora Therapeutics
Biora Therapeutics is the biotech company that is reimagining therapeutics. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients’ lives. Biora envisions a world where patients have access to needle-free drug delivery and better therapeutic outcomes.

For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter.

Safe Harbor Statement or Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations of our research and development efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of precision medicine, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding future revenue generating opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, the ongoing COVID-19 pandemic, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC.

Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com
(646) 627-8390

Media Contact
media@bioratherapeutics.com